Key result
The 1998 Cochrane Albumin Review's conclusion that albumin causes a 5% excess mortality in critically ill patients is critiqued as being based on flawed evidence and inappropriate endpoints.
Why the study?
Does albumin infusion increase mortality in critically ill patients compared to crystalloids?
Does albumin infusion increase mortality in critically ill patients compared to crystalloids?
Answers are grounded in this paper and cite their sources.
This editorial strongly criticizes the methodology and conclusions of the highly influential 1998 Cochrane Albumin Review, arguing that its finding of increased mortality with albumin in critical illness is fundamentally flawed.
The Cochrane 1998 Albumin Review -not all it was cracked up to be In 1995 Neil Soni wrote an Editorial in the British Medical Journal [1] entitled 'Wonderful albumin?not all it was cracked up to be'.In doing so, he lit the fuse that resulted in the explosion caused by the publication of the Cochrane Injuries Group Albumin Reviewers' (CIGAR) meta-analysis 3 years later [2].Soni was asked by the BMJ to peer review the CIGAR review, and his opinion, which was overruled, was that it should not be published.The CIGAR review appeared in the BMJ on 25 July 1998, and the conclusions were described by the Editor as 'suitably tentative'.The main one was that albumin in critical illness kills more people than it saves.The media immediately seized on this clear message and trumpeted it abroad before most doctors had read the review.On 24 July 1998, The Times (London) reported that the review 'suggests that up to 30 000 patients in Britain alone have died because they were treated with human albumin solution'.Seldom has an article in a medical journal provoked so great an impact or caused so much concern, presumably to patients, and certainly to doctors in intensive care units.Ian Roberts, the review's principal author, had warned the UK Department of Health of the mortality findings the previous April and later accused it of dragging its feet for not responding.This resulted in the Observer (London) headline on 26 July 1998, which stated '300 die as health chiefs dither'.Commenting on the results of CIGAR, Roberts was reported as saying, 'We were amazed but totally confident we are accurate … having studied all the evidence I am sure we are right'.Events since then have shown that he did not study all the evidence and may well have been wrong.The Cochrane reviewers said that the clinical use of albumin should be confined to a large blinded randomized clinical trial; no such trial has been started in Europe in the ensuing 4 years, which is not surprising in view of the media's response and the comments by Iain Chalmers, the Director of the UK
No takes yet. Share an insight, caveat, or question.
P.J. Horsey (2002) conducted an editorial in Critical illness and hypovolemia. Albumin vs. Crystalloids or non-albumin fluids was evaluated. The 1998 Cochrane Albumin Review's conclusion that albumin causes a 5% excess mortality in critically ill patients is critiqued as being based on flawed evidence and inappropriate endpoints.
Synapse has enriched 10 related papers. Consider them for comparative context: